Clinical Trials
10 trialsNCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00503451 2020-12-19
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01341834 2018-04-24
Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors
National Cancer Centre, Singapore
Phase 1 Unknown
NCT01032148 2017-01-12
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Roswell Park Cancer Institute
Phase 1 Terminated
NCT01321346 2015-11-24
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT01504776 2014-09-19
BUS48T
Augusta University
Phase 1 Completed
NCT01884428 2014-01-29
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
Istituto Clinico Humanitas
Phase 1 Unknown
NCT00962507 2013-02-15
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT00412997 2012-11-27
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Novartis
Phase 1 Completed
NCT00472368 2012-05-01
A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589
Novartis
Phase 1 Completed